Key Financial Figures - Consolidated
Quarterly Performance (Q2 FY27 vs Q2 FY26):
- Revenue from operations: ₹8,917.85 lakhs (vs ₹5,775.01 lakhs in Q2 FY26)
- Total income: ₹8,845.92 lakhs (vs ₹5,787.57 lakhs in Q2 FY26)
- Profit before tax: ₹691.73 lakhs (vs ₹284.76 lakhs in Q2 FY26)
- Profit for the period: ₹430.06 lakhs (vs ₹382.71 lakhs in Q2 FY26)
- Basic EPS: ₹3.20 (vs ₹2.85 in Q2 FY26)
- Diluted EPS: ₹3.20 (vs ₹2.85 in Q2 FY26)
Half-Yearly Performance (H1 FY27 vs H1 FY26):
- Revenue from operations: ₹16,159.41 lakhs (vs ₹11,542.51 lakhs in H1 FY26)
- Total income: ₹16,464.02 lakhs (vs ₹11,820.21 lakhs in H1 FY26)
- Profit before tax: ₹1,274.72 lakhs (vs ₹821.29 lakhs in H1 FY26)
- Profit for the period: ₹1,002.69 lakhs (vs ₹781.73 lakhs in H1 FY26)
- Basic EPS: ₹7.46 (vs ₹5.81 in H1 FY26)
- Diluted EPS: ₹7.46 (vs ₹5.81 in H1 FY26)
Key Financial Figures - Standalone
Quarterly Performance (Q2 FY27 vs Q2 FY26):
- Revenue from operations: ₹7,881.55 lakhs (vs ₹4,893.32 lakhs in Q2 FY26)
- Profit before tax: ₹552.13 lakhs (vs ₹158.78 lakhs in Q2 FY26)
- Profit for the period: ₹310.97 lakhs (vs ₹263.12 lakhs in Q2 FY26)
- Basic EPS: ₹2.31 (vs ₹1.96 in Q2 FY26)
Half-Yearly Performance (H1 FY27 vs H1 FY26):
- Revenue from operations: ₹14,178.44 lakhs (vs ₹9,785.35 lakhs in H1 FY26)
- Profit before tax: ₹1,007.29 lakhs (vs ₹616.05 lakhs in H1 FY26)
- Profit for the period: ₹761.31 lakhs (vs ₹580.07 lakhs in H1 FY26)
- Basic EPS: ₹5.66 (vs ₹4.31 in H1 FY26)
Segment Performance (Consolidated)
Q2 FY27 Segment Revenue:
- Specialty Chemical: ₹7,807.27 lakhs
- Animal Health: ₹1,110.57 lakhs
- Total: ₹8,917.85 lakhs
Q2 FY27 Segment Results (PBIT):
- Specialty Chemical: ₹623.79 lakhs
- Animal Health: ₹139.86 lakhs
- Total Segment Results: ₹763.66 lakhs
Balance Sheet Highlights (Consolidated)
- Total assets as of September 30, 2026: ₹23,510.00 lakhs (vs ₹21,942.02 lakhs as of March 31, 2026)
- Equity share capital: ₹672.41 lakhs (unchanged)
- Other equity: ₹16,769.79 lakhs (vs ₹16,021.70 lakhs as of March 31, 2026)
- Total equity: ₹17,442.20 lakhs (vs ₹16,694.11 lakhs as of March 31, 2026)
Meeting Details
- Board meeting held on October 30, 2026
- Meeting commenced at 10:30 AM and concluded at 4:25 PM
- Trading window closure: Until November 1, 2026 (48 hours post board meeting outcome)
Business Segments
The Group is engaged in two reportable business segments:
1. Specialty Chemicals
2. Animal Health (Vitamins & Minerals, Probiotic and Prebiotic Enzymes, Feed Additives and Nutrition products)
Subsidiary Information
As of September 30, 2026, the company has one subsidiary: Chembond Biosciences Limited, whose financial results are consolidated.
ESOP Scheme
The company granted stock options under Chembond - ESOP 2025 scheme, with employee compensation expense recognized in Employee Benefits Expense.
Tax Status
The company has decided not to opt for the new tax structure under Section 200 of the Income Tax Act, 2025.
Cash Flow Highlights
Consolidated (H1 FY27):
- Net cash from operating activities: ₹1,239.68 lakhs
- Net cash used in investing activities: ₹(541.52) lakhs
- Net cash used in financing activities: ₹(1,018.13) lakhs
- Net decrease in cash: ₹(589.57) lakhs
Standalone (H1 FY27):
- Net cash from operating activities: ₹917.38 lakhs
- Net cash used in investing activities: ₹(794.74) lakhs
- Net cash used in financing activities: ₹(175.36) lakhs
- Net decrease in cash: ₹(277.72) lakhs